These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18538948)

  • 81. STING Agonists as Cancer Therapeutics.
    Amouzegar A; Chelvanambi M; Filderman JN; Storkus WJ; Luke JJ
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070756
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Magnetic Resonance Imaging for Translational Research in Oncology.
    Fiordelisi MF; Cavaliere C; Auletta L; Basso L; Salvatore M
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31698697
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
    Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
    Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo.
    Papaevangelou E; Boult JKR; Whitley GS; Robinson SP; Howe FA
    Angiogenesis; 2018 Nov; 21(4):737-749. PubMed ID: 29721731
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
    Yang S; Lin J; Lu F; Han Z; Fu C; Gu H
    Contrast Media Mol Imaging; 2017; 2017():9265098. PubMed ID: 29097941
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Improving tumour heterogeneity MRI assessment with histograms.
    Just N
    Br J Cancer; 2014 Dec; 111(12):2205-13. PubMed ID: 25268373
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.
    Emblem KE; Farrar CT; Gerstner ER; Batchelor TT; Borra RJ; Rosen BR; Sorensen AG; Jain RK
    Nat Rev Clin Oncol; 2014 Oct; 11(10):566-84. PubMed ID: 25113840
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High-field small animal magnetic resonance oncology studies.
    Bokacheva L; Ackerstaff E; LeKaye HC; Zakian K; Koutcher JA
    Phys Med Biol; 2014 Jan; 59(2):R65-R127. PubMed ID: 24374985
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
    Boult JK; Terkelsen J; Walker-Samuel S; Bradley DP; Robinson SP
    PLoS One; 2013; 8(4):e63024. PubMed ID: 23638177
    [TBL] [Abstract][Full Text] [Related]  

  • 90. MRI measurements of vessel calibre in tumour xenografts: comparison with vascular corrosion casting.
    Burrell JS; Bradley RS; Walker-Samuel S; Jamin Y; Baker LC; Boult JK; Withers PJ; Halliday J; Waterton JC; Robinson SP
    Microvasc Res; 2012 Nov; 84(3):323-9. PubMed ID: 22921880
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.
    Thompson G; Mills SJ; Coope DJ; O'Connor JP; Jackson A
    Br J Radiol; 2011 Dec; 84 Spec No 2(Spec Iss 2):S127-44. PubMed ID: 22433824
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
    Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
    Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
    McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
    Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
    McPhail LD; Griffiths JR; Robinson SP
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results].
    Schmitz SA
    Rofo; 2003 Apr; 175(4):469-76. PubMed ID: 12677500
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antivascular therapy of cancer: DMXAA.
    Baguley BC
    Lancet Oncol; 2003 Mar; 4(3):141-8. PubMed ID: 12623359
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model.
    Howe FA; McPhail LD; Griffiths JR; McIntyre DJ; Robinson SP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1470-6. PubMed ID: 18538948
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Susceptibility contrast magnetic resonance imaging determination of fractional tumor blood volume: a noninvasive imaging biomarker of response to the vascular disrupting agent ZD6126.
    Robinson SP; Howe FA; Griffiths JR; Ryan AJ; Waterton JC
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):872-9. PubMed ID: 17889267
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.